Navigation Links
Drug has ability to cure type of leukemia

Irvine, Calif. In people with chronic myeloid leukemia (CML), the drug Imatinib has been shown to drive cancer into remission, but the disease often returns when treatment is stopped. New research by UC Irvine scientists indicates that Imatinib could cure CML under certain circumstances if it is taken over a long enough period of time.

Mathematician Natalia Komarova and biologist Dominik Wodarz also developed a tool that eventually could help doctors determine which combination of drugs would be most beneficial to a CML patient, and they determined why, in some cases, Imatinib does not block cancer growth. The results of their study will appear Oct. 3 in the journal PLoS ONE.

CML is a quick-progressing cancer that starts in the bone marrow and moves into the blood. The disease proceeds in three stages, the last one characterized by patient survival of only a few months. In 2007, an estimated 4,570 people in the United States will develop CML, and 490 people will die from it, according to the National Cancer Institute, a division of the U.S. National Institutes of Health.

The drug Imatinib is a promising cancer treatment because it has few side effects, and it specifically targets cancer cells. In their study, the UCI scientists focused on Imatinib and the behavior of cancerous stem cells. Just as normal stem cells maintain organs and a functioning body, cancer stem cells are thought to maintain cancer growth and are tough to kill with treatment.

Many scientists believe that Imatinib can kill regular cancer cells but not stem cells. When treatment ends, the remaining stem cells can produce more cancer cells, thus exacerbating the disease. According to this view, there is no hope to cure CML.

The UCI scientists, however, believe Imatinib can kill cancerous stem cells but not when the stem cells temporarily stop dividing, a state known as quiescence. All cancerous stem cells have the ability to enter the quiescent state. Evidence indicates that when such sleeping stem cells wake up, Imatinib can kill them.

In their paper, the scientists present a mathematical formula that can calculate how long it would take to kill all of the stem cells and cure the cancer. This length of time which could be different for each patient is based on how often the cancerous stem cells fall asleep and how quickly they wake up. Once the scientists can test their theory with patients, they will be able to determine how long the cure might take.

There is evidence that a complete cure is possible. Several patients have been reported to have no symptoms after two months without therapy, which is thought to suggest a complete cure, Komarova said. This evidence supports our theory. Basically, one has to be on therapy long enough for all of the stem cells to wake up and be killed by the drug.

In addition to sleeping stem cells, another barrier to eradication by Imatinib is that cancer cells can mutate to become unresponsive to certain drugs. Conventional thought is that if sleeping stem cells prolong a cure, other cancer cells will have ample time to mutate and become drug resistant.

The UCI scientists, however, have proved this theory wrong. Their calculations show that mutant cells develop early on, in many cases before the patients know they are sick, and do not develop during the treatment process. Using mathematics, they developed a way to calculate the probability that certain mutations exist in a patient. Based on this, one can determine what course of treatment should be used to overcome the resistance.

The model requires the number of cancer cells that exist, how fast the cells divide and die, and how fast they go to sleep and wake up, Wodarz said. Once you have those numbers, you can determine how many drugs to use in combination to make sure drug resistant mutants do not become problems.


Contact: Jennifer Fitzenberger
Public Library of Science

Related medicine news :

1. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
2. Alcoholics are prone to disability
3. Hypertension drugs could lower Disability
4. Running delays disability in the aged
5. Restricted Activity Predicts Disability
6. Adding contrast improves ultrasounds ability to detect prostate cancer
7. CoQ10 bioavailability increased by Nanotechnology
8. Amputation may depend on availability of vascular surgeons
9. The growing availability of Fake drugs in the market
10. Soya Found To Affect Womens Ability To Conceive: Professor
11. Obesity More Likely to Cause Disability than Death in Elderly
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion Bootie , the ... celebration of the early holiday shopping season. Starting Wednesday November 25th, Bunion Booties ... Black Friday promotional pricing is in addition to any automatic discounts applied when ...
(Date:11/24/2015)... ... , ... Dr. Todd S. Afferica, a noted general dentist in Norcross, ... Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental ... other traditional cutting tools, such as the scalpel and high-speed drill, which can both ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Charitable giving ... charitable donations are made in the last five weeks of the year totalling over ... created in 2012 to connect the nation’s charities with those individuals who want to ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced that Dr. Christine Milligan, ... East Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... N.Y. , Nov. 24, 2015 Avery ... System, is pleased to announce the appointment of ... Dr. ... pediatric cardiology at Children,s Hospital, Uppsala University, Uppsala and ... From 1984-1986, he was a fellow at the Cardiovascular ...
(Date:11/24/2015)... India , November 24, 2015 ... . --> adds Latest Guidebook ... report of 217 pages published in November 2015 ... its online business intelligence library at ... one of the fastest growing global economies with ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
Breaking Medicine Technology: